Cue Biopharma (CUE): Officer filed to sell ~$52K
Sumita Ray, Officer at Cue Biopharma, filed to sell ~$52K of Cue Biopharma shares.
- ~$52K
- planned to sell · 1,844 shares, around Oct 12, 2026
- Planned for
- Oct 12, 2026
- Notice filed
- Oct 13, 2026
What stands out in this filing
- The planned sale is 0.02% of the company's shares outstanding, as stated on the notice.
- How the shares were acquired, per the notice: Restricted Stock Units vesting under registered plan.
- The notice says the shares were received as pay (stock awards or options).
- Broker named on the notice: Maxim Group LLC.
- Notice filed Oct 13, 2026 for a sale planned around Oct 12, 2026.
- Remarks on the notice: The proposed sales reported represent shares to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The purpose of the proposed sa.
- A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 14, 2026Company filing · Form 8-K · ResultsReported its results
- Oct 8, 20265% stakeMark E. Strome reported a passive stake (13G) of 8.5%
- Oct 12, 2026Insider · 3 peopleInsiders: 4 sales (~$389K)
What came next
- Nov 10, 20265% stakeBleichroeder LP reported a passive stake (13G) of 8.8%
- Nov 16, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 16, 20265% stakeBALYASNY ASSET MANAGEMENT L.P. reported a passive stake (13G) of 5.9%
- Nov 16, 20265% stakeDRIEHAUS CAPITAL MANAGEMENT LLC reported a passive stake (13G) of 4.0%
- Nov 16, 20265% stakeCormorant Asset Management, LP reported a passive stake (13G) of 10.0%
How to read SEC Form 144
Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.
Full guide: What is an SEC Form 144?
What else is on file for Cue Biopharma
For Cue Biopharma, OQRO holds 6 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CUE page.
How this filing works
Explore the data
Common questions
Which Cue Biopharma (CUE) insider traded, and how much?
Sumita Ray, Officer at Cue Biopharma, filed to sell ~$52K of Cue Biopharma shares. 1,844 shares, Form 144 notice of a planned sale.
When did it happen, and when was it made public?
Planned for: Oct 12, 2026. Notice filed: Oct 13, 2026. That is 1 day between the two dates.
What stands out in this filing?
The planned sale is 0.02% of the company's shares outstanding, as stated on the notice. How the shares were acquired, per the notice: Restricted Stock Units vesting under registered plan. The notice says the shares were received as pay (stock awards or options).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Cue Biopharma recently?
For Cue Biopharma, OQRO holds 6 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the CUE page.
Does this mean CUE stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Cue Biopharma
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Form 4Oct 15, 2026
- SEC Form 4Oct 15, 2026
- SEC Form 4Oct 15, 2026
Everything OQRO holds on this company is on its CUE page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
